27F3611B-6483-47F5-A58E-A74B5165514A
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 42.73981603153745
- age_years
- 62
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.462
- E2F_TARGETS+0.405
- NOTCH_SIGNALING+0.380
- MYC_TARGETS_V1+0.363
- HEDGEHOG_SIGNALING+0.358
- MITOTIC_SPINDLE+0.328
- MYC_TARGETS_V2+0.319
- PANCREAS_BETA_CELLS+0.304
- UV_RESPONSE_DN+0.299
- MTORC1_SIGNALING+0.296
Top 10 suppressed
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.340
- KRAS_SIGNALING_DN-0.283
- COAGULATION-0.281
- MYOGENESIS-0.237
- INTERFERON_ALPHA_RESPONSE-0.196
- ANGIOGENESIS-0.185
- APICAL_JUNCTION-0.173
- IL6_JAK_STAT3_SIGNALING-0.167
- TNFA_SIGNALING_VIA_NFKB-0.151
- INTERFERON_GAMMA_RESPONSE-0.142
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | A5D67B9F-5558-48FC-81A3-642D1903DA1F | — | — | 0.899 |
| 2 | E79FE058-F03E-45F3-A939-356B0427E1B7 | — | — | 0.898 |
| 3 | CD628EE7-84DE-4D82-840B-73718D006B6F | — | — | 0.897 |
| 4 | 0EF566D2-B40C-4BA1-8314-05AAE647869D | — | — | 0.895 |
| 5 | 5EDF36F3-D370-4907-BDA1-8D5FD2B80513 | — | — | 0.891 |
| 6 | BFC86E5F-1A88-4E87-A8C2-2434EC5D95BE | — | — | 0.886 |
| 7 | SRR934777 | — | — | 0.884 |
| 8 | DE406E2B-39AF-4A24-B2BE-0F7CDCBE9D85 | — | — | 0.882 |
| 9 | 46BEFC7F-2F51-4331-BA86-9823EC5781B3 | — | — | 0.881 |
| 10 | 6E8A9288-C2F1-4DDE-B52B-7656DB802FB4 | — | — | 0.861 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.462 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.405 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.380 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.363 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.358 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.328 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.319 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.304 | Cobimetinib | — uncovered |
| UV_RESPONSE_DN | 0.299 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.296 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.291 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.272 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.231 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.214 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.213 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.171 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.171 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.163 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.144 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.127 | Inavolisib | — uncovered |